Human epidermal growth factor receptor 2 (HER2) positivity, accounting for approximately 15–20% of breast cancers, is defined by HER2 protein overexpression measured by immunohistochemistry (IHC) status (IHC3+) or by fluorescence in situ hybridization (FISH) analysis. Here, ERBB2 is linked to breast carcinoma.